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Summary 
HLA-A2 § melanomas express common melanoma-associated  antigens (Ags) recognized in vitro 
by autologous cytotoxic T lymphocytes (CTL). However, it is not known whether tumor Ags 
can drive in vivo a selective  accumulation/expansion of Ag-specific, tumor-infiltrating T lymphocytes 
(TIL). Therefore, to evaluate this possibility,  39 CTL clones isolated from several independent 
mixed lymphocyte tumor cultures (MLTC) of TIL and peripheral blood lymphocytes (PBL) of 
an HLA-A2 + melanoma patient  and selected  for T  cell receptor (TCR)-dependent, HLA- 
restricted tumor lysis, were used for analysis of TCR c~ and ~  chain structure by the cDNA 
polymerase chain reaction (PCR)  technique with variable  gene-specific primers followed by 
sequencing. Despite absence of oligoclonality in fresh TIL and PBL, as well as in T  ceils of 
day 28 MLTC (day of cloning), sequence analysis of TCR c~ and ~ chains of TIL clones revealed 
a dominance of a major category of melanoma-specific,  HLA-A2-restricted T  cells expressing 
a Vc~8.2/JotAP511/Cot  and Vf12.1/DB1/J31.1/C/31  TCR. The same TCR was also found in 
2 out of 14 PBL clones. The other PBL clones employed a Vow2.1 gene segment associated with 
either Vfl13.2,  14, or w22. Clones A81 (Vce2.1/JotIGRJoL04/Ccr and V314/D31/Jfll.2/Cj31) 
and A21  (Vce8.2/JoeAP511/Col  and V/32.1/D/31/J31.1/C31),  representative of the two most 
frequent TCR of PBL and TIL, respectively, expressed different lyric patterns, but both were 
HLA-A2  restricted  and  lysed  only  HLA-A2 +  melanomas  and  normal  melanocytes,  thus 
indicating recognition of two distinct HLA-A2-associated and tissue-related  Ags. Finally, by 
the inverse PCR technique, the specific TCR 3  chain (V32.1/Dfll/J31.1/C3I)  expressed by 
the dominant TIL clone was found to represent 19 and 18.4% of all V/32 sequences expressed 
in the fresh tumor sample and in the purified TIL, respectively, but <0.19% of Vfl2 + sequences 
expressed  in  PBL.  These  results  are  consistent  with  the  hypothesis  that  a  clonal 
expansion/accumulation of a melanocyte-lineage-specific and HLA-A2-restricted T  cell clone 
occurred in vivo at the site of tumor growth. 
S 
tudies on the T  cell immune response to human mela- 
noma have provided evidence that the mechanism of rec- 
ognition of melanoma Ags by CTL is similar to that of more 
conventional types of Ags, namely recognition of complexes 
between tumor-associated peptides and MHC class I mole- 
cules by a cell surface heterodimer receptor (TCR) composed 
of an oe and ~ chain (1-4).  The first peptide-HLA complex 
recognized as a melanoma Ag has been recently identified 
(5), but it is likely that melanomas from different patients 
or even from the same patient will express multiple Ags. In 
fact, distinct antigenic determinants, as well as different HLA 
class I alleles acting as restricting elements, have been defined 
on melanoma ceils by autologous T cell clones (1-4, 6,  7). 
Whether or not the degree of complexity of the melanoma 
Ag repertoire will be reflected in a corresponding repertoire 
of distinct TCR recognizing those Ags is unknown, but re- 
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hypothesis that the CTL-mediated response to melanoma is 
polyclonal at the single patient  level.  This evidence comes 
from the observation that different CTL clones from the same 
patient  may have similar antitumor  reactivity but different 
TCR structure  (8). 
Most of the studies that  have addressed the question of 
TCR diversity in melanoma, or in other neoplastic diseases, 
have analyzed fresh or IL-2-cultured tumor-infiltrating T lym- 
phocytes (TIL) 1 in the attempt to identify oligoclonal T cell 
populations characterized by a restricted set of different TCR 
gene segments.  The identification  of such a population  of 
T cells, if present, could facilitate the study of the molecular 
mechanisms  of the immune  response and could provide a 
specific target for new immunotherapeutic strategies.  Indeed, 
in agreement with the possibility of identifying oligoclonal 
T  cell populations in the lymphoid infiltrate,  a preferential 
expression of Vot7 TCR gene segment  has  been found in 
primary human uveal melanoma by PCR using V gene family 
specific  primers  in seven  out of eight patients  studied (9). 
On the other hand, the TCR Vow/V/3 repertoire of fresh TIL 
from metastatic lesions of cutaneous melanoma has been found 
to vary widely even in the same patient  (10,  11). Further- 
more, after long-term culture in IL-2, TIL from metastatic 
melanoma may become oligoclonal in their  TCR f3 chain 
rearrangements  (12-14), although it is difficult to assess the 
mechanism  of this process. 
The analysis of TCR structure of whole TIL populations, 
however, will hardly allow one to link the information  on 
TCR structure  and repertoire with the functional involve- 
ment  of those TCR in the  antitumor  response,  since one 
cannot distinguish between tumor-specific and bystander lym- 
phocytes with no antitumor  reactivity.  Moreover, this ap- 
proach does not allow the association of any defined combi- 
nation  of TCR  ol  and/3  chains  with  a  precise  antigenic 
specificity, and thus fails to provide a clear answer to the ques- 
tion of whether melanoma can drive,  at the site of tumor 
growth,  a preferential  expansion/accumulation  of tumor- 
specific  T  cells recognizing  melanoma Ags. 
To address these issues, we initially determined the Vo~/Jol 
and VjffD/3/Jf3 TCR gene segments employed by a large set 
of TIL or PBL CTL clones from a HLA-A2 + melanoma pa- 
tient. The results indicated that different TCR combinations 
can confer different antitumor specificity.  Moreover, a domi- 
nant HLA-A2-restricted T  cell clone expressing a Vc~8.2/ 
Jc~AP511/Col, VB2.1/DB1/J~l.1/CB1  TCR and directed to 
a  melanocyte-lineage-associated  Ag  could  be  found  in  a 
majority of TIL clones independently isolated from different 
mixed lymphocyte tumor cultures (MLTC). By inverse PCR 
(IPCR), the nudeotide sequence corresponding to the specific 
TCR/3 chain of this dominant TIL clone was found to rep- 
resent  18.4  and  19%  of all  V/32 +  sequences in  the  fresh 
tumor sample and fresh, purified TIL, respectively, compared 
1 Abbreviations used in  this paper: IPCR, inverse PCR.; MLTC, mixed 
lymphocyte tumor culture; TIL, tumor-infiltrating lymphocyte. 
with <0.19%  of V/32 + sequences expressed in PBL. These 
results suggest that the expression on the tumor of a melano- 
cyte-lineage-associated Ag can influence the tissue distribu- 
tion  of a T  cell clone recognizing  that  Ag. 
Materials and Methods 
Neoplastic  Cells.  All mdanoma ceils used in this study were 
isolated from primary or metastatic lesions obtained from patients 
admitted for surgery to the Istituto Nazionah Tumori and were 
established  in  vitro  as  previously  described  (7). In  particular, 
Me9742/1 and Me9742/2 are a LN and a subcutaneous metastatic 
lesion, respectively, from melanoma patient 9742 (HLA-A2, -A24; 
-B13, -B18; -Cw6, -Cw7; -DR7, -DR11; and -DQ4). All tumors 
were kept in culture with RPM11640 (MA Bioproducts, Walkers- 
ville, MD) supplemented with 10% FCS. Normal human mdano- 
cytes isolated from neonatal foreskin were cultured  as described 
(15). The biological and phenotypical characterization of the mela- 
nocytes has been reported  recently (15). 
Lymphocyte Cultures.  PBL and TIL were isolated as described 
(15) from peripheral blood and from one of the metastatic lesion 
(Me9742/2) of patient 9742. Immediately after isolation, PBL and 
TIL were divided into five separated aliquots,  each initially cul- 
tured in 24-well plates (model 3424; Costar  Corp., Cambridge, 
MA)  at  2.5  x  10s-106 ceUs/ml in  2  ml  of RPMI  1640 sup- 
plemented  with 20% pooled human  serum,  antibiotics,  and 50 
IU/ml of rib2 (kindly provided by EuroCetus,  Amsterdam,  The 
Netherlands). PHA (Wellcome Diagnostics, Research Triangle Park, 
NC) at 1/zg/ml was added to one aliquot of TIL and PBL for 
mitogenic stimulation (TIL-PHA, PBL-PHA). MLTC were started 
by adding viable tumor cells at a lymphocyte/tumor ratio of 5:1 
to each of the remaining cultures (named TIbl, -2, -3, -4 and PBL-1, 
-2, -3, -4). All independent MLTC, as well as mitogenic stimula- 
tions,  were later  transferred into  25 cm  2 flasks (model 25100B; 
Bibby Scientific Products Ltd., Stone, UK) and were restimulated 
every 7 d for 3 wk before cloning at the same conditions as above. 
Cloning was carried out from the four independent  MLTC/TIL 
and the four independent  MLTC/PBL cultures by limiting  dilu- 
tions at 5, 1, 0.5, 0.25 cells/well in round-bottomed 96-well plates 
(model 3596; Costar Corp.)  in the presence of 50 IU/ml rIL-2, 
irradiated (3,000 tad) aUogeneic PBL as feeders (5  x  104/well), 
and irradiated (10,000 rad) autologous tumor cells (5  x  10~/well). 
The plates were restimulated with autologous  tumor and feeder 
cells after 1 wk of culture and screened at day 14 for the presence 
of growing clones. Clones were also derived by plating fresh PBL 
at 0.5 and 0.25 cells/well in the presence of aUogeneic irradiated 
PBL, 50 IU/ml rIL-2, and 1/zg/ml PHA. The probability of clo- 
nality for each done was calculated by Poisson statistics as described 
by Taswell et al. (16), and only clones with a p value for clonality 
>0.95 were further analyzed. LAK cells were obtained by culturing 
PBL from normal donors in 500 IU/ml rlL-2. Samples from the 
surgical tumor specimen, freshly isolated TIL and PBL, MLTC and 
PHA cultures,  and T cell clones, maintained  for 2 wk after the 
initial screening in the absence of feeder cells, were stored at -70~ 
and used to extract  total  I~NA.  TIL and PBL clones were also 
cryopreserved for future use. 
Immunofluorescence  Analysis.  Indirect immunofluorescence was 
performed on autologous MLTC, PHA cultures, or T cell clones 
and analyzed on a FACS  |  (Becton Dickinson  & Co., Mountain 
View, CA) as previously described (17). mAbs used were OKT3 
(anti-CD3, CRL8001; American Type Culture Collection (ATCC), 
RockviUe, MD), OKT4 (anti-CD4,  CRLS002;  ATCC),  OKT8 
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Dickinson & Co.). 
Cytotoxicity Assay.  Cytotoxic activity ofMLTC, T cell clones, 
and LAK cells was measured in a standard 4-h slCr-release assay 
on panels of target tumors as previously described (7). Inhibition 
of lysis by mAb to CD3 (OKT3), HLA class I (W6/32; SeraLab, 
Sussex, UK), HLA-A2, (CR.11.351; kindly provided by Dr.  C. 
Rnsso, Cornell University, New York) (18), and HI,  A-DR (D1.12; 
kindly provided by Dr. K. Accolla, University of Verona, Italy) 
(19) was performed as described (7) with mAbs used at the final 
concentration of I/~g/ml. The percent specific  lysis  was calculated 
using the following formula: 100 x  [(Experimental release [cpm] 
-  spontaneous release [cpm])/(maximum release [cpm] -  spon- 
taneous release [cpm])]. 
Results were also expressed in lytic units (LU), where one LU 
is defined as the number of effectors required for 30% lysis and 
the number of LU present in 107 effector cells was calculated. 
RNA  Extraction and eDNA Synthesis.  Total  RNA from the 
different samples was prepared by the method of Chomczynski and 
Sacchi (20) using  R.NAzoFMB (Cinna/Biotecx,  Friendswood, 
TX). Single-stranded cDNA synthesis was carried out on 2 #g 
of total  RNA  with  oligo-dT  and  Moloney murine  leukemia 
virus-derived  reverse transcriptase without  RNase  H  activity 
(MMLV RT RNase H-, Superscript; Gibco BRL, Gaithersburg, 
MD) according to the manufacturer's instructions. After an eth- 
anol precipitation, the cDNA was suspended in 40/~1 water. 
PCR and IPCR.  PCK was carried out by amplification of 
TCg-ot and -/3 cDNA with oligonudeotide primers complemen- 
tary to TCR V and C region sequences (9, 21) in 25/~1 of a reac- 
tion mixture containing 0.5/~1 of cDNA, 200/~M of each dNTP, 
1/~M of each primer, and 0.625 U of Taq polymerase (Ampli Taq) 
on a DNA thermal cycler (all from Perkin Elmer Cetus Corp., 
Emeryville,  CA).  Reaction  mixtures  were  subjected  to  30 
amplification cycles, each consisting of a 1-min denaturation step 
at 95~  a 1-min annealing step at 55~  and a 1-min extension 
step at 72~  Expression of Vo~ or V/~ genes was considered posi- 
tive when a rearranged band (200-500 bp) was visualized on 2% 
agarose gels with ethidium bromide staining.  For some experiments, 
Southern blot analyses were performed by transferring to nylon 
membranes (Hybond N +; Amersham International, Buckingham- 
shire, UK), 2% agarose gels containing a Vo~-Cc~ or V/gCB rear- 
ranged band, and hybridizing the blots with internal C region oli- 
gonucleotides (probes A and 13, respectively, see Table 1) or with 
oligonucleotides  corresponding to the V/Jc~ and WD/JB junctional 
regions (probes C and D, Table 1) of TIL clones expressing a TCR 
composed of Vo~8.2/Jo~AP511/C~ and V~2.1/D~I/JBI.1/CB1. 
IPCR was performed according to the method described by Ue- 
matsu (22). Briefly,  double-stranded  cDNA was synthesized  by stan- 
dard methods (23) from 1/~g of total RNA, blunt-ended with 
T4 DNA polymerase (New England Biolabs Inc., Beverly,  MA), 
and circularized with T4 DNA ligase (Gibco BRL) in a volume 
of 10/~1. The ligated material (1 #1) was used as PCR template 
in a 50-/~1 reaction mixture. The couple of C region/3 chain primers 
used are identical to the ones described  by Uematsu et al. (24) and 
are listed in Table 1 as oligonudeotides E (forward primer) and 
F (inverse primer), Oligonudeotides E and F contain artificial  SalI 
and Nod sites, respectively,  for subsequent directional cloning. At 
the end of the 30 amplification cycles (denaturation at 95~  for 
40 s, annealing at 62~  for 40 s, and extension at 72~  for I min), 
the Klenow fragment of Escherichia coli DNA polymerase I (New 
England Biolabs Inc.) was added to ensure full-length DNA syn- 
thesis. 
Cloning of PCR and IPCR Amplified Products.  The amplified 
products of PCR obtained with V and C gene specific  primers (9, 
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21) were ligated to pCR200  TM vector (TA doning kit; Invitrogen, 
San Diego, CA) which was subsequently used to transform E. coli 
competent ceils. The PCR 5' V region primer used in conjunction 
with C/3 for the cloning of V/32 sequences to allow family desig- 
nation was: 5' ATGCTGCTGCTTCTGCTGCTTCTG 3'. Phsmid 
DNA extracted from white colonies was spotted into Hybond N + 
nylon membranes using a minifold slot blotter (model SRC 072; 
Schleicher & Schuell, Inc., Keene, NH) and hybridized with in- 
ternal Ca and CB ~ZP-labeled oligonucleotides (probes A and 13, 
Table 1). Sequence  determination was performed on plasmid DNA 
from positive colonies. IPCK products were purified by phenol ex- 
traction, precipitated  with ethanol, and digested  with SalI and NotI 
(New England Biolabs Inc.). Fragments of expected sizes for the 
cDNAs (700 bp for/~ chain sequences) were separated  by electropho- 
resis onto DEAE-cellulose membrane (NA-45 DEAE, Schleicher 
& Schuell, Inc.) through an agarose gel of the appropriate concen- 
tration.  Recovered DNA fragments were ligated to phagescript 
vector arms (Stratagene, La Jolla, CA) obtained by SalI and NotI 
digestion. Phages were grown on Epicurian coli Xbl-Blue compe- 
tent cells (Stratagene). A total of 100,000-500,000 clones were ob- 
tained per microgram of RNA. Recombinant plaques were trans- 
ferred to nitrocellulose  filters  (Schleicher  & Schudl, Inc.) as described 
(23). Membranes were hybridized with C~ (probe B) or with oli- 
gonucleotides specific  for either V/3 2 (probe G) or for the spedfic 
/3 junctional region of V/32.1/D/31/J/~l.1/C/31 TIL clones (probe 
D) as specified  in Table 1. The frequency of V/32 gene usage was 
calculated from the ratio of the numbers of plaques positive with 
V/~2 and CB oligonucleotides (G +/B +) and the frequency of TIL 
clone junctional  region usage from the ratio of the numbers of 
plaques  positive with  the  specific V/D/JB  and  VB2  probe 
(D+/G+).  Single plaques were picked and grown up and recom- 
binant phage DNA was purified for DNA sequence determination. 
Sequencing Reactions.  Sequencing  reactions were performed  with 
Sequenase 2.0 (United States Biochemical  Corp., Cleveland, OH) 
by the dideoxy chain termination, procedure and N sequences  were 
compared with gene data bank entries (GenBank,  Los Alamos,  NM; 
EMBL, Heidelberg, Germany)  and to available  published  V (25-33) 
and J TCR gene segments (26-31, 34). 
Oligonudeotides.  All oligonudeotides used were prepared on an 
automated DNA synthesizer (model 380A; Applied Biosystems, 
Foster City, CA). Sequences  of  oligonucleotides  used as hybridiza- 
tion probes, IPCR, and sequencing primers are shown in Table 
1, whereas sequences of specific  Vcd -~ Vot22, Ca, V/31 ~  V/320, 
C/8 PCK primers are listed elsewhere (9, 21). For hybridization, 
oligonucleotides were endlabeled with [32p]ATP (Amersham In- 
ternational) and T4-polynucleotide kinase (New England Biolabs 
Inc.). Hybridization and washing conditions in order to match their 
target sequence perfectly were chosen according to the length and 
GC content,  as described by Sambrook et al. (23). 
In particular, filters containing IPCR cDNA libraries were pre- 
hybridized for 5 h and then hybridized overnight at 42~  in a so- 
lution containing 3.2x  SSC for probe D, 0.63x  SSC for probe 
G, and 2.5x  SSC for probe I3. In addition, prehybridization and 
hybridization buffer contained 5 x  Denhardt's solution, 1% SDS, 
50 mM Tris-HC1, pH 7.5, and 100/~g/ml salmon sperm DNA. 
32p-labeled oligonudeotide probes were added to the hybridization 
buffer. Filters were then washed twice at room temperature and 
twice at 42~  in a washing solution containing 0.1% SDS and 
the SSC concentration used for hybridization. 
Results 
TCR  Vot and V~ Usage by Fresh and Long-Term  Cultured 
TIL and PBL from Patient 9742.  MLTC lines TIL-1, -2, -3, -4 and PBL-1,  -2, -3, -4 were generated by culturing four 
independent aliquots of fresh TIL and PBL of patient 9742 
with autologous melanoma cells (Me9742/2) and rlL-2. Each 
MLTC line was examined for TCR repertoire expression at 
day 28, day of cloning, and compared with uncultured TIL 
and PBL. This analysis was performed to see whether or not 
in vitro restimulation with autologous tumor is accompa- 
nied by oligoclonal expansion of T  cells and to control for 
variability among multiple long-term cultures derived from 
the same pool of lymphocytes. An aliquot of either TIL or 
PBL, cultured for the same period of time in the presence 
of PHA, was included as control for polyclonal, Ag-indepen- 
dent stimulation, cDNAs were thus obtained from fresh TIL 
and PBL, from all MLTC and PHA lines, and were amplified 
by PCR for 30 cycles using Vow1 to Vo~22 and Vfll to Vfl20 
specific primers in combination with a Col or a Cfl primer, 
respectively. Southern blots were hybridized with internal 
oligonucleotide  probes for Cc~ (probe A, Table 1), Cfl (probe 
B, Table 1) in order to ascertain the specificity of amplification. 
The results obtained with fresh TIL (Fig.  1) indicated that 
their TCR Vo~ and Vfl repertoire was similar to that seen 
on fresh PBL (Fig. 2) and, as described in a preliminary re- 
port (35), not oligoclonal. Furthermore, no oligoclonality 
was found in either population after in vitro restimulation 
with autologous melanoma (Figs. 1 and 2) since most of V~t 
and Vfl families present in fresh lymphocytes were still ex- 
pressed after 28 d of MLTC. However, differences in the in- 
tensity of the hybridization signals were consistently observed. 
Increase of the hybridization signal of Vo~ 5, 11, and 14, ei- 
ther absence or decrease in Vo~ 6, 9,  12, and 15 and Vfl4, 
10, 11, 17, 18, and 19 could be detected in at least three out 
of four MLTC-TIL cultures (Fig.  1). Variations in MLTC- 
PBL cultures involved the increase of Vo~14 and the decrease 
or absence of V~x15 and V/34, 10, and 17. A consistent in- 
crease of Vc~2 was also observed in PBL-1, -3, and -4 (Fig. 
2). The increase or decrease of the hybridization signals ap- 
peared to be associated with culture in the presence of autol- 
ogous tumor since stimulation of TIL with PHA for the same 
period of time (28 d) failed to modify any of the above men- 
tioned families and reflected the TCR Vc~ and V~3 usage of 
fresh TIL (Fig. 1). The MLTC lines from TIL and PBL, all 
expressing  a  predominant  CD3 +,  CD8 +,  TCR-cff~3 + 
phenotype (data not shown), were also tested for cytotox- 
icity against two different autologous lesions (Me9742/2 and 
Me9742/1) and six allogeneic melanomas. All MLTC lines 
from TIL and at least two of the MLTC lines from PBL (PBL-1 
and -2) displayed a preferential  lysis of the two autologous 
metastatic cell lines and of the only HLA-A2-matched al- 
logeneic melanoma (Me10538) (Table 2). TIL and PBL cul- 
tured with PHA and IL-2, but without autologous tumor 
cells, displayed a borderline cytotoxic activity on all targets. 
Taken together, these data indicate that a preferential lysis 
of HLA-A2 +  melanomas can be the result of all  MLTC 
from TIL and of at least two MLTC from PBL. This cyto- 
lytic specificity, however, was not associated with oligoclo- 
nality at the level of TCIL. Therefore, we argued that only 
the analysis of CTL clones from the different MLTC could 
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1234  TIL Overexpress a Melanocyte-specific TCR./3  Sequence Figure 1.  TCR  Vot  and  V/3 
repertoire of fresh TIL, of day 28 
MLTC  from  TIL (TIIr  -2, -3, -4) 
and of day 28 PHA-activated  TIL, 
as detected  by Southern  blot anal- 
ysis of PCIL-amplified  cDNA with 
TCR Vot (1-22) -Cot  and VB (1-20) 
-Cfl primers. Hybridization  was 
performed  with Cot (probe  A, Table 
1) or Cfl (probe  B, Table 1) internal 
oligonucleotides. 
establish the correlation between functional specificity of the 
effectors and the structure of the corresponding TCR. 
TCR Vot and V~ Usage by Antimelanoma T Cell Clones. 
From all TIL and PBL lines previously analyzed, a total of 
112 dones with a p  value for clonality >0.95 were derived. 
Of these clones,  38 were selected for TCR Vot/VB analysis 
(24 clones from TIL and 14 from PBL) on the basis of (a) 
cytotoxic activity on the autologous tumor, and (b) inhibi- 
tion of lysis by anti-CD3 and anti-HLA class I mAb. A T 
cell done (clone 119), obtained by direct cloning of fresh PBL 
with PHA, was also included in the analysis. All 39  CTL 
dones  expressed  a  CD3 +,  CD4-,  CD8 +,  TCR-ot//~ + 
phenotype (data not shown) and, as shown in Table 3, dis- 
played cytotoxic activity on the autologous melanoma with 
no or borderline activity on K562. Lysis of autologous mela- 
noma by all these clones was specifically blocked by anti-CD3 
Figure  2.  TCR. Vot  and  VB 
repertoire of fresh PBL and of day 
28 MLTC  from  PBL (PBI.,1, -2, -3, 
-4)  as detected by Southern blot 
analysis of PCR-amplified cDNA 
with TCR Vot (1-22) -Cot and V/3 
(1-20) -CB primers. Hybridization 
was performed  with Cot (probe A, 
Table 1) or C/3 (probe 13, Table 1) 
internal oligonucleotides. 
1235  Semi et al. Table 2.  Lysis of Autologous (9742/2,  9742/1) and Allogeneic Melanomas by TIL and PBL Cultures at day 28 of MLTC 
Melanoma targets 
Effectors  9742/2*  9742/1"  665/1  1402  10538*  4405  15392  1007 
TIL-1  1249,  812  98  291  2375  84  11  <1 
TIL-2  861  459  123  26  491  112  8  <1 
TIL-3  1846  1252  89  24  1569  36  19  <1 
TIL-4  744  388  <1  <1  324  <1  <1  <1 
TIL-PHA  2  3  124  24  <1  53  3  <1 
PBL-1  1077  1053  613  569  1069  447  245  21 
PBL-2  2051  1691  556  652  2211  553  158  6 
PBL-3  3793  2065  2462  3359  1997  1926  1357  367 
PBL-4  1974  2104  970  1267  3198  1065  619  239 
PBL-PHA  <1  <1  19  8  12  14  1  <1 
Lysis of autologous metastatic lesions (9742/2 and 9742/1) and of allogeneic  melanomas (665/1, 1402, 10538, 4405, 15392, and 1007) by MLTC 
from TIL ( -  1,  - 2,  - 3,  - 4) and from PBL ( - 1,  - 2,  - 3,  - 4) and by PHA-activated TIL and PBL was tested in a 4-h slCr-release assay at 
four different E/T ratios ranging from 50:1 to 0.4:1. 
* HLA-A2  § melanoma cell lines. 
* Results of cytotoxic assays are expressed as LU/107 cells. 
Table 3.  Lyric Activity and TCR  V Cene  Usage of 24 TIL Clones and of 15 PBL Clones 
Targets 
CTL  9742/2  +  9742/2  +  TCR* 
MLTC  Clone  9742/2  anti-CD3*  anti-HLA*  K562  Vc~, VB 
TIL-1 
TIL-2 
A21  43 s  12  13  12  8,  2 
A26  41  13  4  12  8,  2 
A16  35  12  15  14  8,  2 
A27  34  10  15  8  8,  2 
A14  34  5  9  10  8,  2 
A24  33  8  16  10  8,  2 
A2  32  9  20  16  8,  2 
A18  29  11  18  17  8,  2 
A23  27  4  14  8  8,  2 
A8  27  7  8  10  8,  2 
A3  27  9  12  15  8,  2 
A37  26  7  8  11  8,  2 
A36  24  3  2  5  8, - 
A39  23  8  8  9  8,  2 
A5  22  4  6  10  8,  2 
A25  43  11  11  11  14,  2 
A48  25  1  2  6  8,  2 
A50  24  0  8  16  8,  2 
continued 
1236  TIL Overexpress a Melanocyte-specific  TCR ~ Sequence Table  3.  (continued) 
Targets 
CTL  9742/2  +  9742/2  +  TCR* 
MLTC  Clone  9742/2  anti-CD3*  anti-HLA*  K562  Vex, V/~ 
A58  24  1  8  6  8,  2 
A44  19  2  5  10  8,  2 
A54  15  0  4  13  8,  2 
TIL-3  A62  16  1  5  7  8,  2 
TIL-4  A72  32  10  15  11  8, 2 
A70  31  4  12  6  8, 2 
PBL-1  A96  54  35  28  4  2,  13.21 
A100  31  7  20  8  2,  13.2￿82 
A89  23  2  1  2  2,  13.21 
A81  40  8  22  4  2,  14 
A103  49  21  25  7  2,  14 
A94  47  18  27  7  2,  14 
A83  43  17  22  12  2,  14 
A91  43  7  19  6  2,  14 
A109  40  6  9  5  2,  14 
A80  30  3  4  6  2,  14 
A75  33  4  8  2  2,  14 
A78  33  3  5  4  2 6,  3 14 
A93  25  3  3  2  8,  2 
PBL-4  A147  21  5  11  17  8,'2 
PBL-PHA  119  35  5  8  5  2,  w221 
CTL clones isolated by cloning lymphocytes  from MLTC TIL-1, -2, -3, and -4, PBL-1 and -4, and PHA-activated  PBL were tested for lysis of 
autologous tumor (9742/2) and of K562 cells at the E/T ratio of 10:1 in a 4-h slCr-release assay. 
* Inhibition of lysis of autologous tumor was tested after preincubation of CTL clones with anti-CD3 mAb (OKT3) or of the tumor target with 
anti-HLA class I mAb (w6/32). 
t TCK Va and V~ expression of each done was determined by PCK as described in Material and Methods. 
S Results expressed as percent lysis. Underlined values represent significant inhibition of lysis in comparison to lysis of 9742/2 in the absence of 
Abs (SNK test, p  =  0.01). 
I TCK V~ expression of each clone was determined by IPCK as described in Material and Methods. 
(OKT3) and by anti-MHC class I (W6/32) mAbs (Table 3). 
The Va and V~ gene segments utilized in TIL and PBL clones 
were examined by PCK, and the results are also  shown in 
Table 3. In agreement with the statistical prediction of do- 
nality, only one a  and ~ rearranged transcript could be de- 
tected in all but one (PBL-1 done A78) of the clones studied. 
The presence of two a  and ~ chain transcripts in clone A78 
is consistent with the hypothesis that it may not represent 
a true clone and, for this reason, it has not been further in- 
vestigated. The variable fl chain expressed by PBL-1 clones 
A96, A100,  and A89 and by the PBL-PHA clone 119 was 
1237  semi et al. 
identified by IPCR since no amplification could be detected 
with the VB primers used. 
All T  cell clones derived from TIL-1, -2,  -3,  and -4 ex- 
pressed a TCR composed by Va8 and VB2 V region genes 
(Table 3), despite the fact that TIL clones were selected from 
four independent MLTC cultures, except for TIL-1 clones 
A25  (Va14/V/~2)  and A36,  for which only the  a  chain 
(VolS/non VB2) could be fully investigated because of the 
low amount of starting material. Moreover, PBL clones A93 
and  A147  derived from two independent  MLTC cultures 
(PBL-1 and -4) expressed the same Va8 and VB2 transcripts ~
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 (Table 3). All other T cell clones, derived from PBL, prefer- 
entially used Vot2joined to either V313.2, V314, or VBw22 
(Table 3).  No clones expressing Vcr  and only two clones 
expressing V32 were found in 15 TIL clones derived from 
the same patient and lacking specificity for the autologous 
melanoma (data  not shown). 
Sequencing of TCR  cr and ~  cDNAs  of TIL  and PBL 
Clones.  Nucleotide sequence of TCR ot and ~ cDNAs in- 
dicated that V~8/V~2 clones A21,  A50, A62, A70, A93, 
and A147 derived from the four independent in vitro MLTC 
cultures of TILs and from two independent cultures of PBLs, 
share exactly the same TCR. In fact, as shown in Fig. 3, not 
only did they use the same Vot and VB family members, 
namely Vot8.2 (27) and a V~2.1 (30) recently designed as 
VB2.1a by Plaza et al. (32), but they had identical oe and 
W(D)/Jjunctional sequences. VotS.2 was rearranged to a Jot 
segment identical to the published JotAP511 segment (26) 
except for a single base substitution, whereas VB2.1 was rear- 
ranged to DB1, J~1.1,  and CB1 (34). DB1 segment was as- 
signed on the basis of requirements for gene rearrangement 
since the exact identification of this region was impossible, 
due both to junctional and N  region diversification  and to 
the short length of the germline segment (25). All remaining 
Vot8/V32 TIL clones did share the same junctional region 
as assessed by hybridization of Southern blots containing 
Vot8-Cot or V32-C3 rearranged bands with oligonudeotides 
C  and D  (Table  1),  specific for  the junctional region of 
Vot8.2/Jc~AP511/Ca or VB2/D31/JBl.1/C31 chains, respec- 
tively (data not shown). Two other TCR configurations were 
identified by sequence analysis of PBL-1 clones, in addition 
to that composed by Vol8/V~2. In their ot chain, usage of 
the same V family member, Vc~2.1 (27) and presence of N 
region nucleotides at the V/J junction that create codons for 
a shared amino acid could be observed, whereas the/3 chain 
included V~13.2 (31) and V~14 (30) that belong to a sub- 
group of structurally related VB families (36) and the same 
JB1.2 gene segments. Apart from these similarities, both a 
and/J chain junctional regions are different in sequence and 
length. PBL-PHA clone 119 shared with PBL-1 clones the 
usage of Vot2.1 but employed the recently described VB w22 
region (33) and was highly diverse in junctional sequences. 
No predominant structural features were present when se- 
quence of dominant TIL clones was compared with that of 
other TIL or PBL clones. As summarized in Table 4, only 
six different functional TCR are found among melanoma- 
specific and HLA class I-restricted T cell clones derived from 
TIL or PBL of a melanoma patient. 
The Vcr8.2/Vl~2.1 + and Vcr2.1/Vl~14 + Clones  from  TIL 
and  PBL  Are  HLA-A2  Restricted and  Recognize Distinct 
Melanocyte-Lineage-Specific Ags.  PBL clones A75, A81, A83, 
A94,  and A103  (sharing a Vot2.1/IGRJc~04/Cc~  - V~14/ 
D~/1/J~l.2/C/31 TCR, Fig. 3) and TIL clones A37 and A54 
(sharing a Vc~8.2/JotAP511/Cce  - V~2.1/D~I/J~I.1/CB1 
TCR (Fig. 3) have been recently shown to be HLA-A2 re- 
stricted and to recognize Ags expressed on autologous mela- 
noma cells and on HLA-A2-matched normal melanocytes 
(15). Moreover, specificity analysis of PBL clone A81 revealed 
that the antigen recognized was present on the majority of 
HLA-A2 aUogeneic melanomas (15). We thus investigated 
whether TIL clone A21, representative of the dominant TCR 
found  in  TIL  (i.e.,  Vc~8.2/JolAP511/Ccr  -  VB2.1/D~I/ 
JBI.1/C~I), expressed a similar or different pattern of lytic 
Table 4.  Summary  of TCR cr ancl  ~  Chain Composition in Melanoma.specific CTL Clones Isolated  from ML TC of TIL and PBL and from 
PHA-activated PBL 
TCR composition* 
CTL clones 
isolated from  Va  Jc~  VB  JB  Cfl  Frequency* 
TIL-1  8.2  AP511  2.1  1.1  1  14/16 
TIL-2  8.2  AP511  2.1  1.1  1  5/5 
TIL-3  8.2  AP511  2.1  1.1  1  1/1 
TIL-4  8.2  AP511  2.1  1.1  1  2/2 
PBL-1  8.2  AP511  2.1  1.1  1  1/12 
PBL-4  8.2  AP511  2.1  1.1  1  1/1 
TIL-1  8.1  JotV  1/16 
TIL-1  14  2.1  1.2  1  1/16 
PBL-1  2.1  IGRJod0  13.2  1.2  1  3/12 
PBL-1  2.1  IGRJcr  14  1.2  1  8/12 
PBL-PHA  2.1  Jc~T  w22  2.1  2  1/1 
* Nomenclature and references for the V/~, J/3,  Vot,  and Jot gene segments are in the legend to Fig. 3. 
* No.  of clones expressing the given TCR composition/No, of clones examined from each MLTC or from PHA-activated lymphocytes. 
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V/314/D/31/J/31.2/C/31 PBL clone A81. As shown in Table 
5, cytolysis of the autologous melanoma by clones A21 and 
A81, but not by LAK cells (data not shown), was blocked 
by mAb CR.11.351,  indicating that MHC molecule HLA- 
A2 is involved in the recognition of melanoma Ag(s) by T 
cell clones bearing these types of TCR. Moreover, in agree- 
ment with recognition of Ags expressed in vivo, both clones 
lysed the fresh tumor. However, whereas clone A81 recog- 
nized all allogeneic HLA-A2 + melanomas,  the TIL clone 
A21 lysed significantly  only four out of seven HLA-A2 + 
melanomas. No lysis of HLA-A2- melanomas was observed 
by either clone. Furthermore, confirming the previous results 
obtained with T cell clones A75, A83, and A94 (15), CTL 
A81 and A21 lysed the two HLA-A2 + normal melanocytes 
(FM741 and FM727) but not two HLA-A2- melanocytes 
(FM713 and FM216/a). In addition,  neither clone lysed any 
normal or neoplastic cells of nonmelanocyte lineage, including 
the autologous lymphoblastoid cell line from patient 9742, 
in a panel of 17 targets, even though 11 targets were HLA- 
A2 + (Table 5).  Only a borderline reactivity was  seen by 
clone  A21  on  one  HLA-A2 +  fibroblast  line  (F1338/1). 
Taken together, these data suggest that TIL and PBL clones, 
expressing two different TCR, define distinct antigenic de- 
terminants preferentially expressed in cells of the melanocyte 
lineage. Both Ags are recognized in association  with the HLA- 
A2 restriction element but are distinguishable  on the basis 
of their broad or more restricted distribution on allogeneic 
HLA-A2 + melanomas. 
Concerning the other clones bearing different TCR, PBL 
clone 119 was not HLA-A2 restricted and was shown to recog- 
nize an antigenic determinant in association with a different, 
yet unidentified HLA class I allele (15). TIL clones A36 and 
A25 and PBL clones A96, A100, and A89 could not be tested 
because of the insufficient amount of cells obtained to per- 
form the specificity assay. 
The V/D/J Sequence Associated with the Dominant HLA- 
A2-restricted TIL Clone Is Expressed More in the Tumor Sample 
and Fresh TIL than in PBL.  The identification from distinct 
TIL cultures  of the same dominant done characterized by 
a  Vc~8.2/Jc~AP511/C~-VB2.1/DB1/J~1.1/CBl  TCR sug- 
gests, but does not prove, that a selective in vivo expan- 
sion/accumulation of this T cell occurred before the in vitro 
activation  of the lymphocytes.  To  address this  point,  we 
screened cDNA libraries, constructed by IPCR using RNA 
extracted directly from the Me9742/2 surgical specimen, from 
freshly isolated TIL and from PBL, for B chain expression 
with specific  oligonudeotide probes. Positive plaques for each 
oligonudeotide were then counted. Hybridization with an 
upstream CB probe (probe B, Table 1) showed that >80% 
of the clones contained TCR-~ sequences. As shown in Table 
6,  the V~2 family sequences, as detected by hybridization 
with a V~2-specific oligunudeotide (probe G, Table 1), rep- 
resented 10.2 and 11.7% of the total/3 chains in tumor samples 
and in TIL, respectively, vs. 6.5% in PBL. These results are 
in a similar range of frequency detected by two-color im- 
munofluorescence  followed by FACS  |  analysis using a corn- 
merciaUy  available anti-VB2 mAb (mAb TCR V/32 No. 1149; 
Immunotech, Luminy,  France) in  association with  a PE- 
conjugated anti-CD3 mAb (LEU-4PE No. 7347; Becton Dick- 
inson & Co.). This analysis  indicated that 9% of CD3 + cells 
in PBL and 9.5%  of CD3 + cells in TIL were positive for 
VB2 expression (data not shown). However, the B chain se- 
quence corresponding to the junctional region of the domi- 
nant T cell clone was strikingly overrepresented in the tumor 
infiltrate.  In fact,  19 and 18.4%  of all V/32  + sequences in 
the surgical specimen and in the uncultured purified TIL ex- 
tracted from the same sample were positive with oligonude- 
otide D. By contrast, no hybridizing clones were detected 
among 520  V/~2  +cDNA clones  screened from the PBL 
sample. This indicates that the frequency of this specific se- 
quence in the PBL had to be much lower than in the tumor 
sample and at least lower than 0.19%  (1/520  =  0.00192) 
of all VB2 + sequences expressed in the PBL.  In addition, 
all cDNA clones positive for oligonudeotide D were com- 
prised in the V/32  + B chains and sequence analysis of five 
random oligonudeotide D + cDNA clones confirmed pres- 
ence of the expected sequence (data not shown). To find out 
whether or not the V/32  + sequences that did not hybridize 
with oligonucleotide  D were oligodonal, the primary struc- 
ture of 10 randomly selected V~2 + cDNA clones derived 
from TIL was determined. All TCR V/32 chains sequenced 
were in frame and showed no evidence of clonality since none 
of the 10 sequences examined was repeated (data not shown). 
These results indicate that the sequence corresponding to 
the specific TCR/3 chain expressed by an in vitro dominant 
TIL clone is preferentially  expressed  at the site of tumor growth 
in comparison to peripheral blood. This finding is consistent 
with the hypothesis that this T cell clone may have been sub- 
jected, in vivo, to a selective expansion/accumulation driven 
by an HLA-A2-associated  melanocyte-lineage-specific Ag. 
Discussion 
The present study was aimed at the molecular character- 
ization of TCR expressed by fresh and cultured TIL and PBL 
as well as by CTL clones isolated from MLTC of TIL and 
PBL of an HLA-A2 + melanoma patient in relation to their 
fine specificity and in vivo relevance. The analysis of TCR 
repertoire performed on fresh TIL indicated that the degree 
of diversity of this population of lymphocytes was similar 
to that found in circulating PBL. Furthermore, the same anal- 
ysis performed on independent MLTC revealed that after 28 d 
of culture,  both TIL and PBL were still as heterogeneous 
as uncultured cells in their TCR repertoire. This was in con- 
trast with the emergence of a preferential lytic activity against 
autologous or allogeneic  HLA-A2 + melanomas  observed 
not only in all the TIL cultures, but also in at least two MLTC 
from PBL. These findings suggested that it was not possible 
to link any of the different TCR expressed in these cultures 
with the preferential lytic activity. The panel of clones de- 
rived from MLTC of TIL and PBL provided the opportunity 
to correlate TCR structure with antigenic specificity. De- 
spite the large number of  TCR Vo~ and V/~ families expressed 
1241  Sensi et al. Table  5.  Specificity  of PBL Clone A81  (Vc~2.1/V~14 TCR) and TIL Clone A21  (Vot8.2/V~2.1  TCR) 
Effectors 
HLA-A2 
Target  Histology  expression*  A81  A21 
Me9742/2  Metastatic melanoma  96  33*  20 
Me9742/2  Metastatic melanoma  96  6s  0  s 
Fresh Me9742/2  Metastatic melanoma  96  20  13 
Me13294  Metastatic melanoma  95  18  3 
Me18732  Metastatic melanoma  95  27  5 
Me8959  Metastatic melanoma  95  24  0 
Me16938  Metastatic melanoma  93  65  39 
Me3046/2  Metastatic melanoma  92  50  26 
Me14932  Metastatic melanoma  94  42  9 
Me10538  Primary melanoma  96  11  23 
Me1402/R  Primary melanoma  0  0  0 
Me13443  Metastatic melanoma  0  0  0 
Me4024  Metastatic melanoma  0  0  3 
Me665/1  Metastatic melanoma  0  3  6 
Me1340  Metastatic melanoma  0  0  0 
Me1811  Metastatic melanoma  4  0  2 
FM216/a  Normal melanocyte  0  1  0 
FM713  Normal melanocyte  0  0  2 
FM741  Normal melanocyte  98  27  8 
FM727  Normal melanocyte  96  40  20 
Reca458  Renal carcinoma  82  1  6 
RecaSor  Renal carcinoma  93  0  2 
RecaMar  Renal carcinoma  17  0  5 
HT29  Colon carcinoma  0  2  1 
A431  Epidermoid carcinoma  0  1  5 
SKBR3  Breast carcinoma  13  0  7 
CALU3  Lung carcinoma  91  4  0 
Ovca432  Ovarian carcinoma  2  0  0 
Skov3  Ovarian carcinoma  91  0  1 
Igrovl  Ovarian carcinoma  0  0  6 
N592  Small cell lung carcinoma  10  2  3 
H446  Small cell lung carcinoma  0  0  2 
Re458  Normal kidney cells  83  0  6 
F1338/1  Fibroblasts  86  1  10 
LCL9742  EBV-transformed B  cells  95  2  0 
LCL10538  EBV-transformed B  cells  85  0  0 
LCL1811  EBV-transformed B  cells  2  2  0 
Specificity of CTL clones A81 and A21 from patient  9742 was tested in a 4-h slCr-release assay at the E/T ratio of 10:1. 
* Reactivity of different cells with the mAb CRll.351 (anti-HLA-A2) is expressed as percent positive cells by cytofluorimetric analysis. All targets 
in the panel were positive for HLA-class I antigens as detected by the mAb w6/32 (data not shown). 
* Results expressed as percent lysis. Underlined values are significantly  different (SNK test, p  =  0.01) from spontaneous release of each target. Results 
of the lysis of autologous melanoma and on melanocytes by A81 were already published (15, Table 2) but are listed again for a clearer comparison 
with the lytic activity of clone A21. 
S Lysis in the presence of 1/~g/ml of anti-HLA-A2 mAb CRll.351 was significantly different from lysis of the same target in the absence of Ab. 
LCL9742, LCL10538, and LCL1811 are lymphoblastoid cell lines autologous, respectively, to the tumors Me9742, Me10538, and Me1811. Re458 
kidney cells are autologous to the tumor Reca458. FM216/a,  FM713, FM741, and FM727 are normal melanocytes isolated from human neonatal 
foreskin. The biological characteristics and phenotype of melanocytes were described (15). 
1242  TIL Overexpress a Melanocyte-specific  TCR B Sequence Table  6.  Frequency of V/~2 + and V~2.1/D~l/J~I.1/C~l  Junctional Region-positive Sequences in the Surgical Specimen, in Fresh 
Uncultured TIL from  the Same Specimen, and in PBL of Melanoma Patient 9742 
Source 
of RNA 
No. of Vfl2  + plaques 
Total No. of C~ § plaques 
No.  of V~2.1/D/~I/JBI.1/CB1 
junctional region-positive  plaques 
Total No. of VB2 § plaques 
Surgical  specimen  300/2950  (10.2%)  57/300  (19%) 
Fresh TIL  245/2096 (11.7%)  45/245 (18.4%) 
Fresh PBL  520/8000 (6.5%)  0/520 
cDNA libraries generated by IPCR with the total RNA extracted from the surgical specimen, from uncultured TIL and from PBL were plated 
and hybridized with oligonucleotides  B (CB), G (VB2), and D (V/D/J junctional region of VB2.1/DB1/J~I.1/C~I + TIL clones). No. of plaques 
positive for each oligonucleotide probe are shown and the percent frequency of the corresponding gene segment is expressed as in parentheses. 
in independent MLTC, the majority of TIL clones as well 
as two independently derived PBL clones, were donotypic, 
sharing not only identical Vce8.2 and V/32.1 chains but also 
identical J and/or D regions. Studies performed with cloned 
T cells (37) as well as by limiting dilution analysis (38) have 
demonstrated that  specific antitumor CTL precursors  are 
present in PBL and in TIL of  cancer patients. However, when 
the antigenic specificity is similar, the knowledge of the mo- 
lecular composition of  the TCR is mandatory to assess whether 
or not specific CTL clones found in PBL or in TIL represent 
copies of the same T cell. The evidence  described in this study, 
namely that the same T cell clone may be found in the pe- 
riphery and at the tumor site but with different frequency, 
is consistent with the possibility that tumor-associated Ags 
can induce a bias in the tissue distribution of T cells recog- 
nizing them. 
The analysis of the TCR structure of different T cell clones 
isolated from the TIL or PBL of patient 9742 indicated that 
the HLA-A2-restricted cytolytic response to the tumor is 
mediated by at least two different TCR. The comparison of 
antigenic specificity of HLA-A2-restricted clones expressing 
these different TCR (PBL clone A81, bearing a Vcx2.1/V~14 
TCR and TIL clone A21, bearing a Vo~8.2/V~2.1 TCR) 
confirms the results recently obtained with other clones from 
the same patient (15) and indicates that these effectors can 
recognize Ags expressed not only on autologous or allogeneic 
HLA-A2 + melanomas, but also on normal HLA-A2  + mela- 
nocytes. Furthermore, the antigenic determinants recognized 
by the two different CTL clones were expressed  with different 
frequency  among HLA-A2 + melanomas.  These findings, 
therefore, are consistent with the hypothesis that the HLA-A2 
molecule may act as a restricting element for more than one 
melanocyte-lineage-associated  Ag and that distinct HLA- 
A2-peptide complexes are recognized by different TCtL. Fur- 
ther evidence supporting the hypothesis that the antigenicity 
of a human melanoma is based on a number of antigenic de- 
terminants recognized by distinct TCR, was provided by the 
analysis of the TCR. expressed  by the non-HLA-A2-restricted 
CTL clone 119 (TCR Vc~2.1/VBw22), whose specificity has 
been recently described (15). This result rules out any corre- 
lation between TCR Vo~2.1 usage and the restricting HLA-A2 
molecule. Although six different TCR are expressed by the 
specific CTL clones characterized in this  study, because of 
an insuf~cient number of cells, no information is available 
on the specificity of TIL clones A25 and A36 and of PBL-1 
clones characterized by Vo12.1/Vf113.2 TCR that share some 
structural features with Vo~2.1/Vf114 TCR. 
The information on the TCR structure of the CTL clones 
allowed us to correlate the antigenic specificity (namely HLA- 
A2-restricted recognition of a melanocyte-lineage-associated 
Ag) of the dominant category of TIL effectors with the rela- 
tive frequency, in vivo, of the specific TCR fl chain sequence 
expressed by the same CTL clones. To analyze whether an- 
titumor T cells expressing TCR gene segments that charac- 
terize dominant TIL clones were enriched in lymphocytes 
obtained directly from the tumor infiltrate, as compared with 
PBL, we hybridized cDNA libraries generated by IPCR with 
specific oligonucleotides  for either TCR Vfl2 or the junc- 
tional  fl region of the dominant TIL done. By this  tech- 
nique we could show that the specific junctional Vfl2.1/ 
Dill~Jr1.1 sequence represented 19 and 18.4% of all Vfl2 + 
cDNA clones in fresh TIL or in the surgical tumor spec- 
imen, respectively. By screening 520 Vfl2 +cDNA plaques 
derived from PBL libraries similarly constructed, no positive 
plaques could be detected, indicating that the frequency of 
this sequence had to be much lower in PBL than in TIL and 
at least lower than 0.19%  (1/520)  of the Vfl2 + sequences 
found in PBL. Interestingly, we found evidence that clones 
expressing this specific Vfl sequence were not absent from 
the peripheral circulation,  as shown by the observation that 
two replicates of an effector bearing the specific  Vfl2.1/Dfll/ 
Jfll.1/Cfl TCR fl chain were present among PBL clones iso- 
lated from the MLTC PBL-1 and PBL-4. 
Taken together, the results obtained by the IPCR tech- 
nique are consistent with the hypothesis that the expression 
on melanoma of a melanocyte-related antigen can alter the 
tissue distribution of a T cell clone recognizing that Ag. This 
process may be due to a phenomenon of progressive and selec- 
tive accumulation of cells from the same circulating  T cell 
clone at the site of tumor growth. This may have led to a 
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V/52.1/D/51/J/51.1  + TCR/5 sequences in the population of 
mRNA extracted from the PBL or, in other words, to a reduc- 
tion in the frequency of the corresponding clone in the cir- 
culating pool. Alternatively, our results may also be explained 
assuming that one or more replicates of the TCR V/52.1/ 
D/51/J/51.1 + CTL clone underwent a phase of clonal expan- 
sion at the site of tumor growth, possibly as the result of 
Ag recognition. Both these processes can also explain the ob- 
servation that the same CTL clone was found as indepen- 
dent replicates in distinct MLTC of TIL, a finding suggesting 
that the same T lymphocyte was present in multiple copies 
in the freshly purified TIL before this population was divided 
into four different MLTC. 
Similar findings, pointing toward a different expression of 
TCR-specific sequences in distinct anatomical districts, have 
been obtained in rheumatoid arthritis (39).  In fact, V/514 + 
T cells have been found in higher frequency in synovial fluid 
of the affected joints than in PBL, and two cDNA clones 
characterized by particular VB/D/5/J/5  sequences accounted 
for 46-72%  of all V/514 + T  cells,  making up >4%  of all 
T  cells in the affected joints (39).  In our analysis, between 
18.4 and 19% of all V/52 + sequences were associated  with 
the tumor-spedfic TCR sequence, thus representing a propor- 
tion of similar magnitude (between 1.93  or 2.15%)  of all 
TCR/3  chains present in the tumor infiltrate. 
The finding that between 2,000 and 8,000 TCR/5 sequences 
had to be screened to detect evidence of selective overexpres- 
sion of a melanoma-specific/5 chain may help to explain the 
lack of oligodonality detected in other studies based on random 
sequencing of a smaller set of TCR transcripts obtained from 
TIL and control PHA blasts (10). In fact, our results indicate 
that in order to find evidence of selective expression of some 
TCR  in the lymphoid infiltrate associated  with  a human 
tumor, information is needed on the sequence of a TCR shown 
to be linked to the recognition of the tumor. This informa- 
tion allowed us to upgrade to at least a factor 10, in compar- 
ison with previous reports (10), the magnitude of the pool 
of TCR-specific transcripts that could be analyzed. 
The concept that specific TCR might be selectively ex- 
pressed at the tumor site has been proposed by a previous 
study (9) showing that ocular melanomas from different pa- 
tients are characterized by a predominant expression of Vol7, 
a V region gene segment different from the ones found ex- 
pressed in the T cell clones of patient 9742.  However, since 
the antigenic specificity of T cells expressing the Voe7 region 
was not assessed, it remains to be established whether T cells 
infiltrating ocular melanoma have similar function and anti- 
genic specificity in comparison with CTL clones described 
in our study. A possibility to be investigated is that normal 
and neoplastic melanocytes associated  with different tissues 
do not express the same set of genes. Therefore, melanomas 
from different tissues might express distinct antigenic profiles 
recognized by distinct sets of TCR. This hypothesis, if proven, 
may reconcile our results with those of Nitta et al. (9). How- 
ever, the issue of which TCR are directed against melanoma- 
associated antigens is likely to be influenced not only by the 
antigenic profile of each tumor, but also by the MHC geno- 
type of each patient. Only the comparison of specific antitumor 
T cells from different patients will clarify the relative contri- 
bution of antigens and HLA alleles to the shaping of the 
antitumor TCR repertoire. 
Although the number of TCR sequences described here 
is too low to draw conclusions on the whole antimelanoma 
T  cell response in patient 9742,  the knowledge of TCR ot 
and  /3  chain  sequences  of  human  HLA-A2  restricted, 
melanoma-specific CTL that recognize shared melanoma Ags 
of broad or more selected distribution provides the molec- 
ular basis for studies aimed at defining whether other HLA- 
A2 + melanoma patients show the same correlation between 
the fine specificity of antitumor T cell clones and the TCR 
gene elements they express.  If so, the findings described in 
this study may have an impact on the development of im- 
proved therapeutic strategies for the adoptive immunotherapy 
of melanoma. 
Finally, the association between the selective accumulation 
of a T cell clone at the tumor site and the peculiar antigenic 
specificity of this effector (namely recognition of Ags expressed 
not only on the neoplastic cells but also on normal melano- 
cytes) raises the intriguing possibility that at least part of 
the host reaction to the tumor may be dependent on the rec- 
ognition of tissue-related self-Ags.  Clearly, as discussed in 
a recent report (15), we do not know whether the Ags rec- 
ognized by our CTL clones on cultured melanocytes are ex- 
pressed in vivo by this cell type. However, a possibility to 
be investigated is that the selective accumulation at the tumor 
site of a CTL done expressing the V/52.1/D/51/J31.1/C/5  "l'~g 
reflects a process that has altered at some step the peripheral 
tolerance to tissue-related self-Ags (40). 
The understanding of the mechanism that underlies both 
the accumulation/expansion at the tumor site of a melanocyte- 
lineage-specific T cell clone and the concomitant failure of 
an effective block of tumor growth at the same site, repre- 
sent the next key issue to be addressed for clarifying the reasons 
of a seemingly insufficient immune response to the metastatic 
lesion. 
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